Open access
111
Views
5
CrossRef citations to date
0
Altmetric
Original Research
Glibenclamide in patients with poorly controlled type 2 diabetes: a 12-week, prospective, single-center, open-label, dose-escalation study
Virendra Rambiritch1 Biomedical Research Ethics Committee, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa
, Breminand Maharaj2 Department of Therapeutics and Medicines Management, University of Kwazulu-Natal, Durban, KwaZulu-Natal, South Africa
& Poobalan Naidoo3 Boehringer-Ingelheim, Medical Affairs, Johannesburg, Gauteng, South AfricaCorrespondence[email protected]
Pages 63-69
|
Published online: 04 Apr 2014
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.